Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

https://doi.org/10.1182/blood-2019-125983

Published: 2019

Journal Articles

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Blood (2019) 134 (Supplement_1): 4092.

https://doi.org/10.1182/blood-2019-123083

Published: 2019

Journal Articles

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Elisa Zuccarello, PhD, Elisa Calcagno, Adolfo Mazzeo, Nebiyu Ali Abshiru, PhD, Jeannie Camarillo, PhD, Neil L Kelleher, PhD, Changhong Qiao, Renu Nandakumar, PhD, Cremers Serge, PhD PharmD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD, PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2018) 132 (Supplement 1): 37.

https://doi.org/10.1182/blood-2018-99-110447

Published: 2018

Journal Articles

Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Emily C. Ayers, MD, Shaoying Li, MD, Jeffrey Medeiros, MD, David A. Bond, MD, Kami J. Maddocks, MD, Pallawi Torka, MD, Angel Mier Hicks, MD, Madeira Curry, Nina D. Wagner-Johnston, MD, Reem Karmali, MD, Amir Behdad, MD, Bita Fakhri, MDMPH, Brad S Kahl, MD, Michael C Churnetski, BS, Jonathon B. Cohen, MDMS, Nishitha Reddy, MD, Dipenkumar Modi, MD, Radhakrishnan Ramchandren, MD, Christina Howlett, PharmD, BCOP, Lori A. Leslie, MD, Samuel Cytryn, Catherine Diefenbach, MD, Rawan Faramand, MD, Julio C. Chavez, MD, Adam J Olszewski, MD, Yang Liu, MD, Stefan Klaus Barta, MDMRCP,MS, Dhruvika Mukhija, MD, Brian T. Hill, MD PhD, Helen Ma, MD, Jennifer E Amengual, MD, Sunita Nathan, MD, Sarit Assouline, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Ashwin Chandar, MD, Kevin A. David, MD, Anshu Giri, MD, Brian T. Hess, MD, Daniel J. Landsburg, MD

Blood (2018) 132 (Supplement 1): 453.

https://doi.org/10.1182/blood-2018-99-115527

Published: 2018

Journal Articles

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Francesca Montanari, MD, Enrica Marchi, MD, PhD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2018-99-116605

Published: 2018

Journal Articles

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Ahmed Sawas, MD, John Kuruvilla, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Francesca Montanari, MD, Kerry J Savage, BSc, MD MSc, Hager Elgedawe, Diego Villa, MD, Michael Crump, MD, Joseph M Connors, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2018-99-117251

Published: 2018

Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2018-99-115269

Published: 2018

Journal Articles

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Enrica Marchi, MD, PhD, Emily Lichtenstein, RN, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Celeste Rojas, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2017) 130 (Supplement 1): 1515.

https://doi.org/10.1182/blood.V130.Suppl_1.1515.1515

Published: 2017

Journal Articles

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Blood (2017) 130 (Supplement 1): 377.

https://doi.org/10.1182/blood.V130.Suppl_1.377.377

Published: 2017

Journal Articles

Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era

James Nathan Gerson, MD, Stefan Klaus Barta, MDMRCP,MS, Diego Villa, Alina S Gerrie, MD, Shaoying Li, MD, Jeffrey Medeiros, MD, Michael Wang, MD, Brian T. Hill, MD PhD, Yazeed Sawalha, MD, Francisco J. Hernandez-Ilizaliturri, MD, Shalin Kothari, MD, Julie M Vose, MD, Timothy S. Fenske, MD, Swapna Narayana Rao, MD, Kami J. Maddocks, MD, David A Bond, MD, Frederick Lansigan, MD, Timothy Burns, MD, Alexandra M Donovan, MD, Amitkumar Mehta, MD, Nishitha Reddy, MD MSCI, MBBS, Daniel J. Landsburg, MD, Martha Glenn, MD, David James Inwards, MD, Kay Ristow, Reem Karmali, MD MS, Jason Kaplan, MD, Elvira Umyarova, MD, Bhargavi Pulluri, MD, Jennifer E Amengual, MD, Jennifer Kimberly Lue, MD, Paolo Caimi, MD, Jonathon B Cohen, MDMS, Oscar Calzada, BS, Elizabeth Handorf, Jennifer Kelly Anderson, MD, Parv Chapani, Veronika Bachanova, MD PhD, Saurabh Rajguru, MD, Michael C Churnetski, BS, Catherine Diefenbach, Martin Bast, Alexandra E. Kovach, MD

Blood (2017) 130 (Supplement 1): 341.

https://doi.org/10.1182/blood.V130.Suppl_1.341.341

Published: 2017

Journal Articles

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Jennifer E Amengual, MD, Renee Lichtenstein, Celeste Rojas, Ahmed Sawas, MD, Changchun Deng, MD PhD, Emily Lichtenstien, Karen Kahn, Jennifer Kimberly Lue, MD, Yuxuan Liu, PhD, Changhong Qiao, Renu Nandakumar, PhD, Serge Cremers, PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 1824.

https://doi.org/10.1182/blood.V128.22.1824.1824

Published: 2016

Journal Articles

Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity

Blood (2016) 128 (22): 3455.

https://doi.org/10.1182/blood.V128.22.3455.3455

Published: 2016

Journal Articles

Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas

Jennifer Kimberly Lue, MD, Sathyen A Prabhu, Yuxuan Liu, PhD, Owen A. O'Connor, MD PhD, Jennifer E Amengual, MD

Blood (2016) 128 (22): 839.

https://doi.org/10.1182/blood.V128.22.839.839

Published: 2016

Journal Articles

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Matko Kalac, MD PhD, Cristine Candland, RN, Lisa Wallace, RN, Elizabeth Gentner, RN, Shreya Shah, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Suzanne Lentzsch, MD PhD, Owen A. O'Connor, MD PhD, Markus Y Mapara, MD PhD

Blood (2016) 128 (22): 5834.

https://doi.org/10.1182/blood.V128.22.5834.5834

Published: 2016

Journal Articles

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses

Lorenzo Falchi, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Emily Lichtenstein, RN, Karen Khan, BSN, Lawrence H. Schwartz, MD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 2999.

https://doi.org/10.1182/blood.V128.22.2999.2999

Published: 2016

Journal Articles

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, MD, Joseph M. Connors, MD, John G. Kuruvilla, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Diego Villa, MDMPH, Michael Crump, MD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 586.

https://doi.org/10.1182/blood.V126.23.586.586

Published: 2015

Journal Articles

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Jennifer E Amengual, MD, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, MS, Maximilian Lombardo, Emily Lichtenstein, RN, Ellen Neylon, NP, Changchun Deng, MD PhD, Ahmed Sawas, MD, Bijal D Shah, Catherine Wheeler, MD, Simon S Jones, PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 1280.

https://doi.org/10.1182/blood.V126.23.1280.1280

Published: 2015

Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD

Blood (2015) 126 (23): 1282.

https://doi.org/10.1182/blood.V126.23.1282.1282

Published: 2015

Journal Articles

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)

Luigi Scotto, PhD, Xavier Jirau-Serrano, BS, Kelly Zullo, MS, Michael Mangone, PhD, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 3703.

https://doi.org/10.1182/blood.V126.23.3703.3703

Published: 2015

Journal Articles

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Jennifer E Amengual, MD, Maximilian Lombardo, Kelly M Zullo, Paul M. Johannet, BA, Sathyen A Prabhu, Gonzalez Yulissa, Luigi Scotto, PhD, Ying Wei, Jimmy Duong, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 3708.

https://doi.org/10.1182/blood.V126.23.3708.3708

Published: 2015

NARROW

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity

Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only